Glucagon‐Like Peptide‐1 (GLP‐1)‐Based Therapeutics: Current Status and Future Opportunities beyond Type 2 Diabetes

No abstract is available for this paper.

• Publication year

  2018

• Venue

  ChemMedChem

• Publication date

  2018-04-06

• Fields of study

  Medicine

• Identifiers
  DOI 10.1002/cmdc.201700781PMID 29430842
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Design of Novel Exendin-Based Dual Glucagon-like Peptide 1 (GLP-1)/Glucagon Receptor Agonists.

  2017cited by this paper
• A novel glucagon-like peptide-1/glucagon receptor dual agonist exhibits weight-lowering and diabetes-protective effects.

  2017cited by this paper
• Effect of Oral Semaglutide Compared With Placebo and Subcutaneous Semaglutide on Glycemic Control in Patients With Type 2 Diabetes: A Randomized Clinical Trial

  2017cited by this paper
• The Sustained Effects of a Dual GIP/GLP-1 Receptor Agonist, NNC0090-2746, in Patients with Type 2 Diabetes.

  2017cited by this paper
• Diabetes and obesity treatment based on dual incretin receptor activation: ‘twincretins’

  2016cited by this paper
• An overview of new GLP-1 receptor agonists for type 2 diabetes

  2016cited by this paper
• Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes.

  2016cited by this paper
• Glucagon-Like Peptide-1 and Its Class B G Protein–Coupled Receptors: A Long March to Therapeutic Successes

  2016cited by this paper
• Unimolecular Polypharmacy for Treatment of Diabetes and Obesity.

  2016cited by this paper
• Once-Daily Liraglutide Versus Lixisenatide as Add-on to Metformin in Type 2 Diabetes: A 26-Week Randomized Controlled Clinical Trial

  2016cited by this paper
• Half‐Life Extension of Biopharmaceuticals using Chemical Methods: Alternatives to PEGylation

  2016cited by this paper
• All in one: Researchers create combination drugs for diabetes and obesity

  2016cited by this paper
• Exendins and exendin analogs for diabetic therapy: a patent review (2012-2015)

  2016cited by this paper
• PEGylated Biopharmaceuticals

  2015cited by this paper
• Discovery of the Once-Weekly Glucagon-Like Peptide-1 (GLP-1) Analogue Semaglutide.

  2015cited by this paper
• A Phase 2, Randomized, Dose-Finding Study of the Novel Once-Weekly Human GLP-1 Analog, Semaglutide, Compared With Placebo and Open-Label Liraglutide in Patients With Type 2 Diabetes

  2015cited by this paper
• GLP-1 Receptor Agonists in Type 2 Diabetes and Beyond – New Insights 2015

  2015cited by this paper
• A clinical review of GLP-1 receptor agonists: efficacy and safety in diabetes and beyond

  2015cited by this paper
• GLP-1 based therapeutics: simultaneously combating T2DM and obesity

  2015cited by this paper
• Fusion Proteins for Half-Life Extension of Biologics as a Strategy to Make Biobetters

  2015cited by this paper
• Peptide therapeutics: current status and future directions.

  2015cited by this paper
• Protein-polymer conjugation-moving beyond PEGylation.

  2015cited by this paper
• Evaluation of PEGylated exendin-4 released from poly (lactic-co-glycolic acid) microspheres for antidiabetic therapy.

  2015cited by this paper
• Lessons learned from the clinical development of oral peptides

  2015cited by this paper
• A Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight Management.

  2015cited by this paper
• A rationally designed monomeric peptide triagonist corrects obesity and diabetes in rodents

  2014cited by this paper
• Glucagon-like Peptide-1 (GLP-1) Analogs: Recent Advances, New Possibilities, and Therapeutic Implications

  2014cited by this paper
• Once-weekly albiglutide in the management of type 2 diabetes: patient considerations

  2014cited by this paper
• Once-weekly dulaglutide versus once-daily liraglutide in metformin-treated patients with type 2 diabetes (AWARD-6): a randomised, open-label, phase 3, non-inferiority trial.

  2014cited by this paper
• A critical appraisal of antihyperglycemic and cardioprotective activities of liraglutide: a glucagon-like peptide-1 analog.

  2014cited by this paper
• Erratum. Efficacy and Safety of Dulaglutide Added Onto Pioglitazone and Metformin Versus Exenatide in Type 2 Diabetes in a Randomized Controlled Trial (AWARD-1). Diabetes Care 2014;37:2159–2167

  2014cited by this paper
• Once-weekly albiglutide versus once-daily liraglutide in patients with type 2 diabetes inadequately controlled on oral drugs (HARMONY 7): a randomised, open-label, multicentre, non-inferiority phase 3 study.

  2014cited by this paper
• Efficacy and Safety of Dulaglutide Added Onto Pioglitazone and Metformin Versus Exenatide in Type 2 Diabetes in a Randomized Controlled Trial (AWARD-1)

  2014cited by this paper
• Future directions for peptide therapeutics development.

  2013cited by this paper
• Coadministration of Glucagon-Like Peptide-1 During Glucagon Infusion in Humans Results in Increased Energy Expenditure and Amelioration of Hyperglycemia

  2013cited by this paper
• Unimolecular Dual Incretins Maximize Metabolic Benefits in Rodents, Monkeys, and Humans

  2013cited by this paper
• A Novel Glucagon-like Peptide-1 (GLP-1)/Glucagon Hybrid Peptide with Triple-acting Agonist Activity at Glucose-dependent Insulinotropic Polypeptide, GLP-1, and Glucagon Receptors and Therapeutic Potential in High Fat-fed Mice*

  2013cited by this paper
• Co-agonist of glucagon and GLP-1 reduces cholesterol and improves insulin sensitivity independent of its effect on appetite and body weight in diet-induced obese C57 mice.

  2013cited by this paper
• Drug release testing methods of polymeric particulate drug formulations

  2013cited by this paper
• Recent advances in understanding GLP-1R (glucagon-like peptide-1 receptor) function.

  2013cited by this paper
• The C-terminal extension of exendin-4 provides additional metabolic stability when added to GLP-1, while there is minimal effect of truncating exendin-4 in anaesthetized pigs.

  2013cited by this paper
• Recent progress and future options in the development of GLP-1 receptor agonists for the treatment of diabesity.

  2013cited by this paper
• Medicinal chemistry of glucagon-like peptide receptor agonists.

  2013cited by this paper
• Unraveling oxyntomodulin, GLP1's enigmatic brother

  2012cited by this paper
• The structure and function of the glucagon‐like peptide‐1 receptor and its ligands

  2012cited by this paper
• Sodium dependent multivitamin transporter (SMVT): a potential target for drug delivery.

  2012cited by this paper
• GLP-1 receptor agonists for individualized treatment of type 2 diabetes mellitus

  2012cited by this paper
• Obesity and type 2 diabetes

  2011cited by this paper
• Glucagon‐like peptide‐1‐based therapies and cardiovascular disease: looking beyond glycaemic control

  2011cited by this paper
• Liraglutide (victoza): the first once-daily incretin mimetic injection for type-2 diabetes.

  2010cited by this paper
• Dulaglutide, a long-acting GLP-1 analog fused with an Fc antibody fragment for the potential treatment of type 2 diabetes.

  2010cited by this paper
• Liraglutide, a GLP‐1 Analogue to Treat Diabetes

  2010cited by this paper
• Metabolism and Excretion of the Once-Daily Human Glucagon-Like Peptide-1 Analog Liraglutide in Healthy Male Subjects and Its In Vitro Degradation by Dipeptidyl Peptidase IV and Neutral Endopeptidase

  2010cited by this paper
• Exenatide LAR: A sustained-release formulation of exenatide for the treatment of type 2 diabetes

  2010cited by this paper
• Novel Glucagon-like Peptide-1 Analog Delivered Orally Reduces Postprandial Glucose Excursions in Porcine and Canine Models

  2010cited by this paper
• Preparation, characterization, and pharmacodynamics of exenatide-loaded poly(DL-lactic-co-glycolic acid) microspheres.

  2010cited by this paper
• A new glucagon and GLP-1 co-agonist eliminates obesity in rodents.

  2009cited by this paper
• Liposomal formulations of glucagon-like peptide-1: improved bioavailability and anti-diabetic effect.

  2009cited by this paper
• Potential of Albiglutide, a Long-Acting GLP-1 Receptor Agonist, in Type 2 Diabetes

  2009cited by this paper
• Glucagon-Like Peptide 1/Glucagon Receptor Dual Agonism Reverses Obesity in Mice

  2009cited by this paper
• An albumin-exendin-4 conjugate engages central and peripheral circuits regulating murine energy and glucose homeostasis.

  2008cited by this paper
• Improved peroral delivery of glucagon-like peptide-1 by site-specific biotin modification: design, preparation, and biological evaluation.

  2008cited by this paper
• Effects of Once-Weekly Dosing of a Long-Acting Release Formulation of Exenatide on Glucose Control and Body Weight in Subjects With Type 2 Diabetes

  2008cited by this paper
• Incretin hormone mimetics and analogues in diabetes therapeutics.

  2007cited by this paper
• Structure and function studies of glucagon‐like peptide‐1 (GLP‐1): the designing of a novel pharmacological agent for the treatment of diabetes

  2005cited by this paper
• Synthesis, characterization, and pharmacokinetic studies of PEGylated glucagon-like peptide-1.

  2005cited by this paper
• Control of Blood Glucose by Novel GLP-1 Delivery Using Biodegradable Triblock Copolymer of PLGA-PEG-PLGA in Type 2 Diabetic Rats

  2004cited by this paper
• Structural requirements of the N-terminal region of GLP-1-[7-37]-NH2 for receptor interaction and cAMP production.

  2004cited by this paper
• Effects of exenatide (exendin-4) on glycemic control over 30 weeks in sulfonylurea-treated patients with type 2 diabetes.

  2004cited by this paper
• Treatment of Type 2 diabetes mellitus with agonists of the GLP-1 receptor or DPP-IV inhibitors

  2004cited by this paper
• Once daily injection of exendin-4 to diabetic mice achieves long-term beneficial effects on blood glucose concentrations

  1999cited by this paper
• Dipeptidyl peptidase IV resistant analogues of glucagon-like peptide-1 which have extended metabolic stability and improved biological activity

  1998cited by this paper
• Structure-activity studies of glucagon-like peptide-1.

  1994cited by this paper
• Oxyntomodulin: a potential hormone from the distal gut. Pharmacokinetics and effects on gastric acid and insulin secretion in man

  1988cited by this paper
• The catabolism of human G immunoglobulins of different heavy chain subclasses. 3. The catabolism of heavy chain disease proteins and of Fc fragments of myeloma proteins.

  1972cited by this paper
• A Continuous Publication, Open Access, Peer-reviewed Journal

  year unknowncited by this paper

• Effects of Dioscorea opposita polysaccharides on insulin resistance and gut microbiota in high-fat-diet induced type 2 diabetic rats.

  2025cites this paper
• Intranasal Absorption Enhancement of Antidiabetic Therapeuticals by the Functional Peptide Segment of Latroeggtoxin-VI.

  2025cites this paper
• Protein–Ligand Interactions in Cardiometabolic Drug Targets: Focus on Weight Loss and Cardioprotection

  2025cites this paper
• Nutritional Approaches to Enhance GLP-1 Analogue Therapy in Obesity: A Narrative Review

  2025cites this paper
• Insulin Analogs and the Mode of Insulin Delivery: Recent Advances and Challenges.

  2024cites this paper
• New insights into nanomedicines for oral delivery of glucagon-like peptide-1 analogs.

  2024cites this paper
• Comparing regional brain uptake of incretin receptor agonists after intranasal delivery in CD-1 mice and the APP/PS1 mouse model of Alzheimer’s disease

  2024cites this paper
• A web-based scoping review assessing the influence of smoking and smoking cessation on antidiabetic drug meabolism: implications for medication efficacy

  2024cites this paper
• The signaling pathways in obesity‐related complications

  2024cites this paper
• Correlation between intestinal flora and GLP-1 receptor agonist dulaglutide in type 2 diabetes mellitus treatment—A preliminary longitudinal study

  2024cites this paper
• Physiology and pharmacology of glucagon-like peptide-1 receptor

  2024cites this paper
• Effect of Semaglutide on High-Fat-Diet-Induced Liver Cancer in Obese Mice

  2024cites this paper
• Dietary impact on fasting and stimulated GLP-1 secretion in different metabolic conditions – a narrative review

  2024cites this paper
• The Therapeutic Potential of GLP-1 Receptor Agonists in the Management of Hidradenitis Suppurativa: A Systematic Review of Anti-Inflammatory and Metabolic Effects

  2024influential citation
• Bioengineered Nanomedicines Targeting the Intestinal Fc Receptor Achieve the Improved Glucoregulatory Effect of Semaglutide in a Type 2 Diabetic Mice Model.

  2024cites this paper
• Cardiovascular Protection with a Long-Acting GLP-1 Receptor Agonist Liraglutide: An Experimental Update

  2023cites this paper
• Brain uptake pharmacokinetics of albiglutide, dulaglutide, tirzepatide, and DA5-CH in the search for new treatments of Alzheimer’s and Parkinson’s diseases

  2023cites this paper
• Cold Exposure and Oral Delivery of GLP-1R Agonists by an Engineered Probiotic Yeast Strain Have Antiobesity Effects in Mice

  2023cites this paper
• Concept for a Unidirectional Release Mucoadhesive Buccal Tablet for Oral Delivery of Antidiabetic Peptide Drugs Such as Insulin, Glucagon-like Peptide 1 (GLP-1), and their Analogs

  2023cites this paper
• Emerging Role of GLP-1 Agonists in Obesity: A Comprehensive Review of Randomised Controlled Trials

  2023cites this paper
• Preparation, structural properties, and in vitro and in vivo activities of peptides against dipeptidyl peptidase IV (DPP-IV) and α-glucosidase: a general review

  2023cites this paper
• Comparing the bioequivalence and safety of liraglutide in healthy Chinese subjects: an open, single-dose, randomized, repeated, two-sequence, two-cycle phase I clinical trial

  2023cites this paper
• The effect of linagliptin on microalbuminuria in patients with diabetic nephropathy: a randomized, double blinded clinical trial

  2023cites this paper
• Sustained release of GLP-1 analog from γ-PGA-PAE copolymers for management of type 2 diabetes.

  2023cites this paper
• Site-specific N-terminal PEGylation-based controlled release of biotherapeutics: An application for GLP-1 delivery to improve pharmacokinetics and prolong hypoglycemic effects.

  2022cites this paper
• Oral delivery of GLP-1R agonist by an engineered probiotic yeast strain has anti-obesity effects in mice

  2022cites this paper
• The modern pharmacological approach to diabetes: innovative methods of monitoring and insulin treatment

  2022cites this paper
• Oral glucagon-like peptide 1 analogue ameliorates glucose intolerance in db/db mice

  2022cites this paper
• Prader–Willi Syndrome in Adults: An Update On Nutritional Treatment and Pharmacological Approach

  2022cites this paper
• Glucagon-like peptide 1 and fibroblast growth factor-21 in non-alcoholic steatohepatitis: An experimental to clinical perspective.

  2022cites this paper
• Effects of Semaglutide on Glycemic Control and Weight Loss in a Patient with Prader-Willi Syndrome: A Case Report.

  2022cites this paper
• α/Sulfono-γ-AA peptide hybrids agonist of GLP-1R with prolonged action both in vitro and in vivo

  2022cites this paper
• Research Progress on Dipeptidyl Peptidase Family: Structure, Function and Xenobiotic Metabolism.

  2021cites this paper
• Efficacy and safety of glucagon‐like peptide‐1/glucagon receptor co‐agonist JNJ‐64565111 in individuals with type 2 diabetes mellitus and obesity: A randomized dose‐ranging study

  2021cites this paper
• Matrine, as a CaSR agonist promotes intestinal GLP-1 secretion and improves insulin resistance in diabetes mellitus.

  2021cites this paper
• Developing GLP-1 Conjugated Self-Assembling Nanofibers Using Copper-Catalyzed Alkyne-Azide Cycloaddition and Evaluation of Their Biological Activity.

  2021cites this paper
• Obesity in Prader–Willi syndrome: physiopathological mechanisms, nutritional and pharmacological approaches

  2021cites this paper
• A quinoxaline-based compound ameliorates bone loss in ovariectomized mice

  2021cites this paper
• The Present and Future Role of Microfluidics for Protein and Peptide-Based Therapeutics and Diagnostics

  2021cites this paper
• Central GLP-1 contributes to improved cognitive function and brain glucose uptake after duodenum-jejunum bypass on obese and diabetic rats.

  2021cites this paper
• Structural principles of insulin formulation and analog design: A century of innovation

  2021cites this paper
• Strategies for the delivery of antidiabetic drugs via intranasal route.

  2021cites this paper
• Oral GLP-1 Analogue Ameliorates Obesity-Induced Diabetes In Db/Db Mouse

  2021cites this paper
• New Horizons: Next-Generation Insulin Analogs: Structural Principles and Clinical Goals.

  2021cites this paper
• Peptide Multimerization as Leads for Therapeutic Development

  2021cites this paper
• Progress in research of gastrointestinal motility regulation

  2020cites this paper
• ACTUALITIES IN ENDOCRINE PHARMACOLOGY: ADVANCES IN THE DEVELOPMENT OF ORAL FORMULATIONS FOR CALCITONIN AND SEMAGLUTIDE.

  2020cites this paper
• Nonalcoholic Fatty Liver Disease in the Post Liver Transplant Patient

  2020cites this paper
• Glucagon-Like Peptide-1 Analog Liraglutide Attenuates Pressure-Overload Induced Cardiac Hypertrophy and Apoptosis through Activating ATP Sensitive Potassium Channels

  2020cites this paper
• A free‐energy landscape for the glucagon‐like peptide 1 receptor GLP1R

  2020cites this paper
• Structural optimization of pyrazolo[1,5-a]pyrimidine derivatives as potent and highly selective DPP-4 inhibitors.

  2020cites this paper
• Is there a role for glucagon-like peptide-1 receptor agonists in the management of diabetic nephropathy?

  2020cites this paper
• Optimised methods for the production and bioconjugation of site-specific, alkyne-modified glucagon-like peptide-1 (GLP-1) analogs to azide-modified delivery platforms using copper-catalysed alkyne-azide cycloaddition.

  2020cites this paper
• An overview of glucagon-like peptide-1 receptor agonists for the treatment of metabolic syndrome: A drug repositioning

  2020cites this paper
• The Cascade System of Osmotic Homeostasis Regulation

  2020cites this paper
• Key milestones in the diabetes research: A comprehensive update

  2020cites this paper
• Glucagon and Glucagon-like Peptide-1 Receptors: Promising Therapeutic Targets for an Effective Management of Diabetes Mellitus.

  2020cites this paper
• The Race to Bash NASH: Emerging Targets and Drug Development in a Complex Liver Disease.

  2020cites this paper
• Peptide-oligourea hybrids analogue of GLP-1 with improved action in vivo

  2019cites this paper
• Ureidopeptide GLP-1 analogues with prolonged activity in vivo via signal bias and altered receptor trafficking

  2019cites this paper
• Trends in Peptide Therapeutics

  2019cites this paper
• Liraglutide protects high-glucose-stimulated fibroblasts by activating the CD36-JNK-AP1 pathway to downregulate P4HA1.

  2019cites this paper
• Glucose metabolism: Normal physiology, diabetic dysregulation, and therapeutic targets

  2019cites this paper
• Glucagon-Like Peptide-1 Receptor Agonists and Strategies To Improve Their Efficiency.

  2019cites this paper
• Engineering PEG-fatty acid stapled, long-acting peptide agonists for G protein-coupled receptors.

  2019cites this paper
• The spatiotemporal control of signalling and trafficking of the GLP-1R

  2019cites this paper
• C-Peptide Area Under the Curve at Glucagon Stimulation Test Predicts Glucose Improvements by GLP-1 Receptor Analogue: A Retrospective Observational Study

  2019cites this paper
• Recent Advances in Half-life Extension Strategies for Therapeutic Peptides and Proteins.

  2019cites this paper
• Glucagon-like peptide-1 receptor activation alleviates lipopolysaccharide-induced acute lung injury in mice via maintenance of endothelial barrier function

  2019cites this paper
• Dissecting the Physiology and Pathophysiology of Glucagon-Like Peptide-1

  2018cites this paper
• Glucagon-Like peptide-1: A new therapeutic target to treat abdominal aortic aneurysm?

  2018cites this paper